Drug Profile

Programmed cell death-1 receptor antagonist - Sorento Thrapeutics

Alternative Names: Sofusa® anti-PD-1

Latest Information Update: 27 Feb 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sorrento Therapeutics
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

27 Jan 2023 Phase-I clinical trials in Cutaneous T-cell lymphoma in USA (Intralymphatic) (Sorrento Therapeutics pipeline, January 2023)
27 Jan 2023 Phase-I clinical trials in Malignant melanoma in USA (Intralymphatic) (Sorrento Therapeutics pipeline, January 2023)
03 Jul 2018 Sorrento Therapeutics acquires Sofusa™ lymphatic drug delivery system from Kimberly-Clark Corporation to develop checkpoint inhibitors and immuno-oncology therapies for cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com